肿瘤内癌症治疗市场在研究期间（2020-2034年）将以31.3%的复合年增长率展现出巨大的增长-动脉网

Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034)

CISION 等信源发布 2025-05-20 05:31



可切换为仅中文







As per DelveInsight's estimates, among the 7MM, the US captured the highest market of intra-tumoral cancer therapies of nearly

根据DelveInsight的估计，在七大市场中，美国占据了近最高的肿瘤内癌症治疗市场份额。

USD 74 million

7400万美元

in 2024, which is expected to increase due to the launch of emerging therapies such as CAN-2409,

2024年，由于CAN-2409等新兴疗法的推出，这一数字预计将增加，

RP1

(vusolimogene oderparepvec), SP-002 (ASN-002), Bizaxofusp (MDNA55), and others.

（vusolimogene oderparepvec）、SP-002（ASN-002）、Bizaxofusp（MDNA55）等。

LAS VEGAS

拉斯维加斯

，

May 19, 2025

2025年5月19日

/PRNewswire/ -- DelveInsight's

/PRNewswire/ -- DelveInsight的

Intra-tumoral Cancer Therapies Market

肿瘤内癌症治疗市场

report includes a comprehensive understanding of current treatment practices, emerging intra-tumoral cancer therapies, market share of individual therapies, and current and forecasted intra-tumoral cancer therapies market size from 2020 to 2034, segmented into 7MM [

报告包括对当前治疗实践、新兴的瘤内癌症疗法、各疗法的市场份额以及2020年至2034年当前和预测的瘤内癌症疗法市场大小的全面理解，细分至7MM [

the United States

美国

, the EU4 (

，欧盟4（

Germany

德国

，

France

法国

，

Italy

意大利

, and

，和

Spain

西班牙

), the

），这个

United Kingdom

英国

, and

，以及

Japan

日本

Key Takeaways from the Intra-tumoral Cancer Therapies Market Report

肿瘤内癌症治疗市场报告的关键要点

Currently, only three Intra-tumoral Cancer Therapies are approved; namely,

目前，仅批准了三种肿瘤内癌症疗法，即

IMLYGIC

咪唑立宾

(Talimogene laherparepvec/T-VEC; Amgen), approved in the US and

（Talimogene laherparepvec/T-VEC；Amgen），在美国获批并

Europe

欧洲

in 2015,

2015年，

DELYTACT

德莱塔克特

(teserpaturev/G47Δ; Daiichi Sankyo) approved in

(teserpaturev/G47Δ；大冢制药) 获批于

Japan

日本

in 2021, and

2021年，和

HENSIFY

HENIFY

在

Europe

欧洲

in 2019.

2019年。

As per DelveInsight's analysis, the total market size of intra-tumoral cancer therapies in the 7MM was

根据DelveInsight的分析，7MM中肿瘤内癌症疗法的总市场规模为

USD 109 million

1.09亿美元

in 2024 and is projected to grow during the forecast period (2025-2034).

在 2024 年，并预计在预测期内（2025-2034 年）增长。

In 2024, the total cases of selected indication (based on current landscape and pipeline activity) were

2024年，所选适应症的总病例数（基于当前情况和研发管线活动）为

8.9 million

890万

in the 7MM, which is anticipated to increase by 2034.

在7MM中，预计到2034年将有所增加。

Leading intra-tumoral cancer therapies companies, such as

领先的肿瘤内癌症治疗公司，如

Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir, Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others, .

扬森、斯坦福制药、Ascend Biopharmaceuticals、Replimune、Highlight Therapeutics、Cytovation ASA、Intensity Therapeutics、Ascendis Pharma、Treovir、Matica Biotechnology、QBiotics、NanOlogy、Lokon Pharma AB、EpicentRx、Medicenna Therapeutics、Philogen S.p.A.、Candel Therapeutics、Lytix Biopharma、Verrica Pharmaceuticals、CEI-SCI，以及其他公司。

and others, are developing novel intra-tumoral cancer therapies that are expected to enter the intra-tumoral cancer therapies market in the coming years.

预计在未来几年内会进入肿瘤内癌症治疗市场。

Some of the key intra-tumoral cancer therapies in the pipeline include

一些正在研发中的关键的肿瘤内癌症治疗方法包括

INT230-6, Vusolimogene oderparepvec

INT230-6，Vusolimogene oderparepvec

(RP1)

（RP1）

，

Nidlegy

尼德尔吉

(Daromun),

（达罗姆），

G207, Ilixadencel

G207，Ilixadencel

(INTUVAX),

(INTUVAX)，

Tigilanol tiglate, SP-002

蒂吉拉诺尔·蒂格莱特，SP-002

(ASN-002),

BO-112, Bizaxofusp

BO-112，Bizaxofusp

(MDNA55), and others.

（MDNA55），以及其他。

在

March 2025

2025年3月

, NANOBIOTIX

，纳米生物技术

announced topline data from the completed dose-escalation portion of a Phase I study, conducted under the sponsorship of The

宣布了由The赞助的I期研究中已完成的剂量递增部分的初步数据，

University of Texas

德克萨斯大学

MD Anderson Cancer Center, evaluating JNJ-1900 (NBTXR3) activated by radiation therapy as a second-line or later (2L+) treatment for patients with locally advanced NSCLC eligible for re-irradiation.

MD安德森癌症中心正在评估由放射治疗激活的JNJ-1900（NBTXR3），作为对适合再照射的局部晚期非小细胞肺癌（NSCLC）患者的二线或后续（2L+）治疗。

在

March 2025

2025年3月

，

NANOBIOTIX

纳米生物技术

announced an amendment to its global licensing agreement with

宣布对其与全球许可协议进行修订

Janssen Pharmaceutica NV.

扬森制药公司

The amendment removes NANOBIOTIX's funding obligation for NANORAY- 312 and releases Johnson & Johnson from select future potential milestone payments while safeguarding NANOBIOTIX's path to sustainable cash flow through significant potential milestone payments.

该修正案取消了NANOBIOTIX对NANORAY-312的资助义务，并免除了约翰逊 & 约翰逊部分未来潜在的里程碑付款，同时通过重要的潜在里程碑付款保障了NANOBIOTIX实现可持续现金流的路径。

在

March 2025

2025年3月

，

Candel Therapeutics

坎德尔治疗学

and

和

IDEA Pharma

灵感制药

announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel's lead asset,

宣布了一项战略商业合作伙伴关系。根据该协议，IDEA 将在 Candel 的主要资产开发和商业化过程中提供战略商业投入，

CAN-2409

。

在

January 2025

2025年1月

, Lokon Pharma AB

，Lokon制药公司

announced that the Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) for the company's product candidate LOAd703 for the treatment of pancreatic cancer.

宣布美国食品药品监督管理局（FDA）已授予公司产品候选物LOAd703用于治疗胰腺癌的快速通道资格（FTD）。

在

January 2025

2025年1月

, Intensity Therapeutics

，强度治疗学

announced that the Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INT230-6, INVINCIBLE-3) without modification based on data reviewed from

宣布数据监测委员会（DMC）基于审查的数据建议继续进行其三期肉瘤试验（INT230-6，INVINCIBLE-3），无需修改。

July 2024

2024年7月

至

December 2024

2024年12月

。

Some factors, such as the

某些因素，例如

precedence of failure of emerging therapies

新兴疗法失败的优先级

，

insufficient knowledge about

关于...的知识不足

Intra-tumoral Cancer Therapies

肿瘤内癌症疗法

，

and

和

several other drawbacks

几个其他缺点

, might hinder the Intra-tumoral Cancer Therapies market growth.

，可能会阻碍肿瘤内癌症治疗市场的发展。

Discover which therapies are expected to grab the intra-tumoral cancer therapies market share @

了解哪些疗法有望占据肿瘤内癌症疗法的市场份额 @

Intra-tumoral Cancer Therapies Market Report

肿瘤内癌症治疗市场报告

Intra-tumoral Cancer Therapies Market Dynamics

肿瘤内癌症治疗市场动态

The intra-tumoral cancer therapies market dynamics are expected to change in the coming years. Various classes of intra-tumoral immunotherapies, including

预计未来几年，肿瘤内癌症治疗市场的动态将会发生变化。各类肿瘤内免疫疗法，包括

radioenhancer nanoparticles, recombinant fusion proteins, oncolytic therapy, gene therapy, synthetic dsRNA complexes,

放射增强纳米颗粒、重组融合蛋白、溶瘤治疗、基因治疗、合成双链RNA复合物，

and others, are currently in preclinical and clinical development. These therapies increase drug concentration and availability within the tumor microenvironment while

和其他疗法目前正处于临床前和临床开发阶段。这些疗法在提高肿瘤微环境中的药物浓度和可用性的同时

limiting systemic exposure and reducing the likelihood of immune-related side effects

限制系统性暴露并减少免疫相关副作用的可能性

in other parts of the body.

在身体的其他部位。

Intra-tumoral therapeutic strategies offer a powerful approach to

肿瘤内治疗策略提供了一种强有力的方法来

in situ

现场

vaccine development

疫苗开发

, utilizing immune-stimulating agents to trigger local and systemic anti-tumor immune responses. Additionally, the

，利用免疫刺激剂触发局部和全身的抗肿瘤免疫反应。此外，

ability of intra-tumoral immunotherapy

肿瘤内免疫治疗的能力

combinations to elicit both T-cell and B-cell antitumor responses presents a potential strategy to overcome immune escape mechanisms, such as the loss of HLA-I expression on tumor cells, which are often associated with immune checkpoint therapy monoclonal antibody monotherapies.

结合引发T细胞和B细胞抗肿瘤反应的组合策略，具有克服免疫逃逸机制的潜力，例如与免疫检查点治疗单克隆抗体单药疗法常相关的肿瘤细胞HLA-I表达缺失。

Furthermore, potential therapies are being investigated, and it is safe to predict that the treatment space will significantly impact the intra-tumoral cancer therapies market during the forecast period. Moreover, the

此外，潜在的治疗方法正在研究中，可以肯定地预测，在预测期内，治疗领域将对肿瘤内癌症治疗市场产生重大影响。此外，

anticipated introduction of emerging therapies

预计新兴疗法的引入

with improved efficacy and a further

随着疗效的提高和进一步的

improvement in the diagnosis rate

诊断率的提高

are expected to drive the growth of the intra-tumoral cancer therapies market in the 7MM.

预计将在7MM中推动瘤内癌症治疗市场的增长。

However, several factors may impede the growth of the intra-tumoral cancer therapies market. The

然而，有几个因素可能会阻碍肿瘤内癌症治疗市场的增长。

lack of standardized guidelines

缺乏标准化的指导方针

for intra-tumoral immunotherapy delivery results in variations in lesion selection, injection frequency, and needle technique, which directly affect treatment outcomes and safety. Patients are required to visit clinics for

用于肿瘤内免疫治疗递送时，会导致病灶选择、注射频率和针头技术的差异，这些因素直接影响治疗效果和安全性。患者需要到诊所就诊以

each dosing session

每次给药时段

, and the administration necessitates both trained radiologists and logistics support alongside skilled physicians. While research into intra-tumoral therapies has grown in recent years, several therapies, such as

，而且管理需要训练有素的放射科医生和后勤支持以及熟练的医生。近年来，虽然对肿瘤内治疗的研究有所增加，但有几种治疗方法，例如

tilsotolimod/Ipilimumab, sotigalimab

蒂索托利莫德/伊匹单抗，索提加利单抗

(APX005M), and

（APX005M），以及

vidutolimod

维杜托利莫德

(CMP-001), have failed clinical trials, impacting the market. Additionally,

(CMP-001) 未能通过临床试验，影响了市场。此外，

tumors with high intra-tumoral heterogeneity

具有高度瘤内异质性的肿瘤

may lead to poorer clinical outcomes for patients.

可能导致患者临床结果较差。

Intra-tumoral Cancer Therapies Therapeutics Market

肿瘤内癌症治疗药物市场

Although significant progress has been made in cancer treatment through methods like surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, many of these treatments still face limitations such as systemic toxicity, inadequate tumor penetration, and poor targeting. These issues contribute to high mortality rates, underscoring the need for more precise and localized treatment options.

尽管通过手术、化疗、放疗、免疫治疗和靶向治疗等方法在癌症治疗方面取得了显著进展，但这些治疗手段仍面临系统性毒性、肿瘤渗透不足以及靶向性差等局限性。这些问题导致了较高的死亡率，凸显了对更精确和局部化治疗方案的需求。

Recently, cancer treatment strategies have increasingly focused on alternative delivery methods, including intra-tumoral administration. This approach is being actively researched, with several therapeutic candidates—such as immune receptor agonists, viral therapies, fusion proteins, monoclonal antibodies, and gene therapies—currently undergoing preclinical and clinical trials..

最近，癌症治疗策略越来越关注替代递送方法，包括瘤内给药。这种方法正在被积极研究，目前有几种治疗候选药物——如免疫受体激动剂、病毒疗法、融合蛋白、单克隆抗体和基因疗法——正在进行临床前和临床试验。

Intra-tumoral immunotherapy, which involves directly delivering agents into or near the tumor site, is emerging as a promising approach. This strategy aims to boost localized immune responses while reducing systemic side effects. The first oncolytic virus,

肿瘤内免疫疗法，即将药物直接递送至肿瘤部位或其附近，正成为一种有前景的方法。该策略旨在增强局部免疫反应，同时减少全身副作用。第一个溶瘤病毒，

IMLYGIC (T-Vec; Amgen)

IMLYGIC（T-Vec；安进）

, was approved by the US FDA for treating unresectable melanoma lesions after surgery, following a Phase III trial. The European Commission approved the treatment of advanced melanoma in 2015. In 2019,

经III期试验后，美国FDA批准了其用于手术后不可切除的黑色素瘤病灶的治疗。欧洲委员会于2015年批准了该药物用于晚期黑色素瘤的治疗。2019年，

Nanobiotix's HENSIFY (NBTXR3)

纳米生物技术公司的HENSIFY（NBTXR3）

, a hafnium oxide nanoparticle therapy combined with radiation, received European approval for soft tissue sarcoma, with plans for data releases through 2025-2026 across multiple cancers. For STS the drug is approved in

，一种含铪氧化物纳米粒子疗法联合放射治疗，已获得欧洲批准用于软组织肉瘤，并计划在2025-2026年发布多种癌症的数据。对于软组织肉瘤，该药物已获批在

Europe

欧洲

but not yet launched. In

但尚未启动。在

Japan

日本

，

DELYTACT (G47∆; Daiichi Sankyo)

DELYTACT（G47∆；第一三共）

was granted conditional approval for malignant glioma, marking the first oncolytic virus for brain cancer, and is still under evaluation for its clinical benefits.

获得了恶性胶质瘤的有条件批准，标志着首个用于脑癌的溶瘤病毒，其临床效益仍在评估中。

IMLYGIC from Amgen is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors. Despite the initial hype for this exciting intra-tumoral mode of cancer gene therapy, IMLYGIC's debut did not translate into much commercial success in the melanoma market. Limitations of the intra-tumoral administration, no statistically significant benefit in overall survival (OS), and the intense competition from immune checkpoint inhibitors (ICIs) due to their efficacy and manageable side effects are some of the main factors for ithe nsignificant revenues of this novel therapy..

安进公司的IMLYGIC是首个也是唯一一个获FDA批准的直接注射到黑色素瘤肿瘤中的病毒疗法。尽管这种瘤内注射的癌症基因疗法模式最初引起了极大的关注，但IMLYGIC的上市并未在黑色素瘤市场转化为显著的商业成功。瘤内给药方式的局限性、总生存期（OS）未显示出统计学上的显著益处，以及来自免疫检查点抑制剂（ICIs）的激烈竞争（因其疗效和可控的副作用），是这种新型疗法收入不尽如人意的一些主要原因。

Learn more about the FDA-approved intra-tumoral cancer therapies @

了解更多关于FDA批准的瘤内癌症疗法 @

Intra-tumoral Cancer Therapies Treatment

肿瘤内癌症治疗

Key Emerging Intra-tumoral Cancer Therapies and Companies

关键的新兴肿瘤内癌症疗法和公司

The emerging pipeline of intra-tumoral cancer therapies is robust, including drugs from key players such as

肿瘤内癌症治疗的新兴渠道非常丰富，包括来自主要参与者如下的药物：

Candel Therapeutics

Candel治疗公司

(CAN-2409),

Lytix Biopharma/Verrica Pharmaceuticals

Lytix生物制药/ Verrica制药公司

(LTX-315 [VP-315]),

(LTX-315 [VP-315])，

CEI-SCI

(MULTIKINE),

（MULTIKINE），

Philogen

菲洛根

(Daromun [NIDLEGY; a combo of L19IL2 + L19TNF]),

（达罗木 [NIDLEGY；L19IL2 + L19TNF的组合]），

Replimune

(

RP2

and

和

RP1

[vusolimogene oderparepvec]),

[维索利莫基因或德帕雷普vec]，

Highlight Therapeutics

高光治疗学

(BO-112),

（BO-112），

Cytovation ASA

赛拓生技公司

(CY-101),

Intensity Therapeutics

强度治疗学

(INT230-6),

Ascendis Pharma

Ascendis制药公司

(TransCon IL-2 β⁄γ),

（TransCon IL-2 β/γ），

Treovir/Matica Biotechnology

特雷欧维/Matica生物技术

(G207),

（G207），

QBiotics

(Tigilanol tiglate),

（蒂吉拉诺尔·蒂格莱特），

NanOlogy

纳米学

(NanoPac),

（NanoPac），

EpicentRx

靶向肿瘤中心

(AdAPT-001),

（AdAPT-001），

Medicenna Therapeutics

Medicenna治疗学

(Bizaxofusp [MDNA55]), and others.

(Bizaxofusp [MDNA55])，以及其他。

RP1

(vusolimogene oderparepvec),

（vusolimogene oderparepvec），

Replimune

瑞普利梅尔

's lead product candidate, is based on a proprietary strain of Herpes Simplex Virus (HSV) engineered with a fusogenic protein (GALV-GP R-) and GM-CSF to enhance tumor killing potency, immunogenicity, and activation of a systemic antitumor immune response. In

的主要候选产品，是基于一种专有的单纯疱疹病毒（HSV）菌株，该菌株通过融合蛋白（GALV-GP R-）和GM-CSF进行基因工程改造，以增强肿瘤杀伤效力、免疫原性，并激活全身性抗肿瘤免疫反应。在

November 2024

2024年11月

, Replimune announced that the FDA granted Breakthrough Therapy Designation (BTD) to

Replimune宣布，FDA授予其突破性疗法认定（BTD）

RP1

in combination with nivolumab for the treatment of advanced melanoma in adult patients who have previously received an anti-PD1 regimen.

与nivolumab联合使用，用于治疗先前已接受过抗PD1方案的成年晚期黑色素瘤患者。

Nidlegy

尼德莱吉

is a biopharmaceutical product, proprietary to

是一种生物制药产品，专有于

Philogen

菲洛根

, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF, which are manufactured independently and which are mixed prior to intralesional administration. In

，用于治疗皮肤癌。它由两种活性成分L19IL2和L19TNF组成，这两种成分分别独立生产，并在瘤内注射前混合。

July 2024

2024年7月

, Philogen and Sun Pharmaceutical announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy.

Philogen和太阳制药宣布，欧洲药品管理局（EMA）已确认受理Nidlegy的上市许可申请（MAA）。

CAN-2409

(Candel Therapeutics) is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the tumor. In

(Candel Therapeutics) 是一种研究性、现成的、复制缺陷型腺病毒，旨在将单纯疱疹病毒胸苷激酶 (HSV-tk) 基因递送到患者特定的肿瘤，并诱导针对该肿瘤的个体化、全身性免疫反应。在

March 2025

2025年3月

, according to the company's corporate highlights, the preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer are underway, with submission expected in Q4 2026.

根据公司的企业亮点，CAN-2409在前列腺癌方面的生物制品许可申请（BLA）准备工作正在进行中，预计将于2026年第四季度提交。

The anticipated launch of these emerging therapies are poised to transform the intra-tumoral cancer therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the intra-tumoral cancer therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出有望在未来几年内改变肿瘤内癌症治疗市场的格局。随着这些尖端疗法不断成熟并获得监管部门的批准，它们预计将重塑肿瘤内癌症治疗市场的面貌，提供新的护理标准，并为医疗创新和经济增长解锁机会。

To know more about intra-tumoral cancer therapies clinical trials, visit @

要了解更多关于肿瘤内癌症治疗的临床试验，请访问 @

Intra-tumoral Cancer Therapies

肿瘤内癌症疗法

Intra-tumoral Cancer Therapies Overview

肿瘤内癌症疗法概述

Cancer is a highly diverse disease, with its signs, symptoms, and treatments varying across different types, making it crucial to create targeted therapies for individual patients. Current treatment options for cancer include immunotherapy, radiotherapy, chemotherapy, targeted drug therapies, and more.

癌症是一种高度多样化的疾病，其体征、症状和治疗方法因类型而异，因此为个别患者制定靶向治疗方案显得尤为重要。目前，癌症的治疗选择包括免疫疗法、放射疗法、化学疗法、靶向药物疗法等。

While these approaches have improved OS and patient outcomes, they still have limitations and are not effective for everyone. Researchers are therefore working to develop new treatments that can overcome these challenges, with intra-tumoral cancer therapies emerging as a promising strategy..

虽然这些方法改善了操作系统和患者预后，但它们仍然有局限性，并非对所有人都有效。因此，研究人员正在努力开发能够克服这些挑战的新疗法，其中肿瘤内癌症治疗正成为一种有前景的策略。

Intra-tumoral immunotherapy represents an innovative approach, where sophisticated antibodies are directly injected into tumors instead of being administered intravenously. This method focuses on delivering immunostimulatory agents straight into primary or metastatic tumor sites to initiate or enhance an antitumor immune response.

肿瘤内免疫治疗是一种创新方法，其中复杂的抗体被直接注射到肿瘤中，而不是静脉注射。该方法专注于将免疫刺激剂直接递送到原发或转移的肿瘤部位，以启动或增强抗肿瘤免疫反应。

Normally, the immune system detects and eliminates early tumors, but in immunosuppressive tumor environments, malignant cells can proliferate undetected. Regulatory T cells (Tregs), drawn to the tumor by chemokines, suppress Antigen-Presenting Cells (APCs) that would otherwise trigger an immune attack on tumor antigens.

通常情况下，免疫系统会检测并消除早期肿瘤，但在具有免疫抑制特性的肿瘤环境中，恶性细胞可以不受察觉地增殖。调节性T细胞（Tregs）被趋化因子吸引到肿瘤处，抑制了原本会触发对肿瘤抗原免疫攻击的抗原呈递细胞（APCs）。

Moreover, tumor cells often release anti-inflammatory and regulatory cytokines like TGF-β and IL-10, which promote tumor growth and inhibit dendritic cell (DC) activation..

此外，肿瘤细胞常释放抗炎和调节性细胞因子，如TGF-β和IL-10，这些因子促进肿瘤生长并抑制树突状细胞（DC）的活化。

To counteract this immunosuppressive environment, immunostimulants can be introduced. These agents work by attracting immune cells to the tumor or by activating the immune system to recognize and destroy cancer cells. Immunostimulants activate immune cells in the presence of tumor antigens, allowing them to travel to lymph nodes, where they stimulate tumor antigen-specific T cells through cross-presentation.

为了对抗这种免疫抑制环境，可以引入免疫刺激剂。这些药物通过吸引免疫细胞到肿瘤部位或激活免疫系统以识别和摧毁癌细胞来发挥作用。免疫刺激剂在肿瘤抗原存在的情况下激活免疫细胞，使它们能够迁移到淋巴结，在那里通过交叉呈递刺激肿瘤抗原特异性T细胞。

These activated T cells can then return to the tumor or spread to distant tumors, leading to the targeted destruction of cancer cells..

这些被激活的T细胞随后可以返回肿瘤或扩散到远处的肿瘤，从而导致癌细胞的靶向破坏。

Intra-tumoral Cancer Therapies Epidemiology Segmentation

肿瘤内癌症治疗流行病学细分

In 2024, the total indication-wise treated cases of Intra-tumoral Cancer Therapies were

2024年，肿瘤内癌症治疗的总适应症治疗病例数为

3.3 million

三百三十万

in the 7MM, which is anticipated to increase by 2034. The intra-tumoral cancer therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

在七大市场中，预计到2034年将有所增长。瘤内癌症治疗市场报告提供了2020-2034年研究期间在七大市场中的流行病学分析，具体分为：

Total Cases of Selected Indications

所选适应症的总病例数

Indication-wise Target Patient Pool of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗的适应症目标患者群体

Indication-wise Treated Cases of Intra-tumoral Cancer Therapies

适应症导向的肿瘤内癌症治疗案例

Intra-tumoral Cancer Therapies Report Metrics

肿瘤内癌症治疗报告指标

Details

详情

Study Period

学习期

2020–2034

Intra-tumoral Cancer Therapies Report Coverage

肿瘤内癌症治疗报告覆盖范围

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

七国集团 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]

Intra-tumoral Cancer Therapies Market CAGR

肿瘤内癌症治疗市场复合年增长率

(in the 7MM)

（在7MM中）

31.3 %

Intra-tumoral Cancer Therapies Market Size in 2024 (in the 7MM)

2024年肿瘤内癌症治疗市场规模（在7个主要市场中）

USD 109 Million

1亿9百万美元

Key Intra-tumoral Cancer Therapies Companies

肿瘤内癌症治疗关键公司

Amgen, Nanobiotix, Daiichi Sankyo, Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir and Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others.

安进、纳米生物、第一三共、杨森、斯坦福制药、Ascend生物制药、Replimune、Highlight Therapeutics、Cytovation ASA、Intensity Therapeutics、Ascendis Pharma、Treovir、Matica生物技术、QBiotics、NanOlogy、Lokon制药、EpicentRx、Medicenna Therapeutics、Philogen S.p.A.、Candel Therapeutics、Lytix Biopharma、Verrica Pharmaceuticals、CEI-SCI等。

Key Intra-tumoral Cancer Therapies

肿瘤内关键癌症治疗方法

IMLYGIC (Talimogene Laherparepvec), DELYTACT (teserpaturev), HENSIFY, SP-002 (ASN-002), RP2, RP1 (vusolimogene oderparepvec), TransCon IL-2 β/γ, BO-112, CY-101, INT230-6, G207, Tigilanol Tiglate, NanoPac, LOAd703, AdAPT-001, Bizaxofusp (MDNA55), Nidlegy (L19IL2/L19TNF), CAN-2409, LTX-315, MULTIKINE and others..

IMLYGIC（Talimogene Laherparepvec）、DELYTACT（teserpaturev）、HENSIFY、SP-002（ASN-002）、RP2、RP1（vusolimogene oderparepvec）、TransCon IL-2 β/γ、BO-112、CY-101、INT230-6、G207、Tigilanol Tiglate、NanoPac、LOAd703、AdAPT-001、Bizaxofusp（MDNA55）、Nidlegy（L19IL2/L19TNF）、CAN-2409、LTX-315、MULTIKINE 等等。

Scope of the

范围

Intra-tumoral Cancer Therapies

肿瘤内癌症疗法

Market Report

市场报告

Intra-tumoral Cancer Therapies Therapeutic Assessment:

肿瘤内癌症疗法治疗评估：

Intra-tumoral current marketed and emerging therapies

肿瘤内当前已上市和新兴的疗法

Intra-tumoral Cancer Therapies

肿瘤内癌症治疗

Market Dynamics:

市场动态：

Conjoint Analysis of Emerging Intra-tumoral Cancer Therapies

新兴肿瘤内癌症疗法的联合分析

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Intra-tumoral Cancer Therapies Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、肿瘤内癌症疗法的市场准入和报销

Discover more about intra-tumoral cancer therapies in development @

了解更多关于正在开发的肿瘤内癌症疗法 @

Intra-tumoral Cancer Therapies Clinical Trials

肿瘤内癌症治疗临床试验

Table of Contents

Key Insights

关键见解

Report Introduction

报告介绍

Executive Summary

执行摘要

Key Events

关键事件

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

Intra-tumoral Cancer Therapy Market Overview at a Glance

肿瘤内癌症治疗市场概况一览

6.1

Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2025

2025年肿瘤内癌症治疗按适应症的市场份额（%）分布

6.2

Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2034

2034年肿瘤内癌症治疗按适应症划分的市场份额（%）分布

Background and Overview

背景与概述

7.1

Introduction

简介

7.2

History of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗史

7.3

Mechanism of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗机制

7.4

Tumor Properties to Consider for Intra-tumoral Cancer Therapies

肿瘤内癌症治疗需要考虑的肿瘤特性

7.5

Categories of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗的分类

7.6

Advantages of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗的优势

7.7

Limitations of Intra-tumoral Cancer Therapies

肿瘤内癌症治疗的局限性

7.8

Emerging Therapies and Future Directions

新兴疗法与未来方向

Epidemiology and Patient Population

流行病学与患者群体

8.1

Key Findings

主要发现

8.2

Assumptions and Rationale

假设与理由

8.3

Epidemiology Scenario in the 7MM

七国流行病学情景

8.3.1

Total Cases of Selected Indications in the 7MM

七大市场中选定适应症的总病例数

8.3.2

Indication-wise Eligible Cases in the 7MM

7MM中的适应症合格病例

8.3.3

Indication-wise Treated Cases in the 7MM

7MM中的按适应症分类的治疗病例

Marketed Therapies

已上市疗法

9.1

Key Cross of Marketed Therapies

已上市疗法的关键交叉

9.2

IMLYGIC (talimogene laherparepvec): Amgen

IMLYGIC（talimogene laherparepvec）：安进

9.2.1

Product Description

产品描述

9.2.2

Regulatory Milestones

监管里程碑

9.2.3

Other Developmental Activities

其他开发活动

9.2.4

Clinical Development Activities

临床开发活动

9.2.4.1

Clinical Trials Information

临床试验信息

9.2.5

Safety and Efficacy

安全性与有效性

9.2.6

Analyst View

分析师观点

9.3

DELYTACT (teserpaturev): Daiichi Sankyo

DELYTACT（特塞尔帕图雷夫）：第一三共

9.3.1

Product Description

产品描述

9.3.2

Regulatory Milestones

监管里程碑

9.3.3

Other Developmental Activities

其他开发活动

9.3.4

Safety and Efficacy

安全性与有效性

9.3.5

Analyst View

分析师观点

Emerging Drugs

新兴药物

10.1

Key Competitors

主要竞争对手

10.2

HENSIFY (JNJ-1900, NBTXR3): NANOBIOTIX/Johnson & Johnson

HENSIFY（JNJ-1900，NBTXR3）：NANOBIOTIX/Johnson & Johnson

10.2.1

Product Description

产品描述

10.2.2

Regulatory Milestones

监管里程碑

10.2.3

Other Developmental Activities

其他开发活动

10.2.4

Clinical Development Activities

临床开发活动

10.2.4.1

Clinical Trials Information

临床试验信息

10.2.5

Safety and Efficacy

安全性与有效性

10.2.6

Analyst View

分析师观点

10.3

INT230-6: Intensity Therapeutics

INT230-6：强度治疗公司

10.3.1

Product Description

产品描述

10.3.2

Other Development Activities

其他开发活动

10.3.3

Clinical Development

临床开发

10.3.3.1

Clinical Trial Information

临床试验信息

10.3.4

Safety and Efficacy

安全性与有效性

10.3.5

Analyst View

分析师观点

10.4

RP1 (vusolimogene oderparepvec): Replimune

RP1（vusolimogene oderparepvec）：Replimune

10.4.1

Product Description

产品描述

10.4.2

Other Developmental Activities

其他开发活动

10.4.3

Clinical Development

临床开发

10.4.3.1

Clinical Trial Information

临床试验信息

10.4.4

Safety and Efficacy

安全性与有效性

10.4.5

Analyst View

分析师观点

10.5

Nidlegy (Daromun): Philogen S.p.A

尼德莱吉（达罗明）：菲洛根股份公司

10.5.1

Product Description

产品描述

10.5.2

Other Developmental Activities

其他开发活动

10.5.3

Clinical Development

临床开发

10.5.3.1

Clinical Trials Information

临床试验信息

10.5.4

Safety and Efficacy

安全性与有效性

10.5.5

Analyst View

分析师观点

10.6

RP2: Replimune

RP2：Replimune

10.6.1

Product Description

产品描述

10.6.2

Other Developmental Activities

其他开发活动

10.6.3

Clinical Development

临床开发

10.6.3.1

Clinical Trial Information

临床试验信息

10.6.4

Safety and Efficacy

安全性与有效性

10.6.5

Analyst View

分析师观点

10.7

Cotsiranib (STP705): Sirnaomics

科茨兰尼布 (STP705): Sirnaomics

10.7.1

Product Description

产品描述

10.7.2

Other Development Activity

其他开发活动

10.7.3

Clinical Development

临床开发

10.7.3.1

Clinical Trial Information

临床试验信息

10.7.4

Safety and Efficacy

安全性与有效性

10.7.5

Analyst View

分析师观点

10.8

BO-112: Highlight Therapeutics

BO-112：Highlight Therapeutics

10.8.1

Product Description

产品描述

10.8.2

Other Developmental Activities

其他开发活动

10.8.3

Clinical Development

临床开发

10.8.3.1

Clinical Trial Information

临床试验信息

10.8.4

Safety and Efficacy

安全性与有效性

10.8.5

Analyst View

分析师观点

10.9

SP-002 (ASN-002): Stamford Pharmaceuticals/Ascend Biopharmaceuticals

SP-002（ASN-002）：斯坦福制药/Ascend生物制药

10.9.1

Product Description

产品描述

10.9.2

Other Developmental Activities

其他开发活动

10.9.3

Clinical Development

临床开发

10.9.3.1

Clinical Trial Information

临床试验信息

10.9.4

Safety and Efficacy

安全性与有效性

10.9.5

Analyst View

分析师观点

10.10

TransCon IL-2 β/γ: Ascendis Pharma

TransCon IL-2 β/γ：Ascendis Pharma

10.10.1

Product Description

产品描述

10.10.2

Other Development Activity

其他开发活动

10.10.3

Clinical Development

临床开发

10.10.3.1

Clinical Trial Information

临床试验信息

10.10.4

Safety and Efficacy

安全性与有效性

10.10.5

Analyst View

分析师观点

10.11

Ilixadencel (INTUVAX): Mendus

Ilixadencel（INTUVAX）：Mendus

10.11.1

Product Description

产品描述

10.11.2

Other Developmental Activities

其他开发活动

10.11.3

Clinical Development

临床开发

10.11.3.1

Clinical Trial Information

临床试验信息

10.11.4

Safety and Efficacy

安全性与有效性

10.11.5

Analyst View

分析师观点

10.12

Tigilanol Tiglate: QBiotics

替吉拉诺尔·蒂格莱特：QBiotics

10.12.1

Product Description

产品描述

10.12.2

Other Development Activity

其他开发活动

10.12.3

Clinical Development

临床开发

10.12.3.1

Clinical Trial Information

临床试验信息

10.12.4

Safety and Efficacy

安全性与有效性

10.12.5

Analyst View

分析师观点

10.13

NanoPac (LSAM-PTX): NanOlogy

NanoPac（LSAM-PTX）：NanOlogy

10.13.1

Product Description

产品描述

10.13.2

Other Developmental Activities

其他发展活动

10.13.3

Clinical Development

临床开发

10.13.3.1

Clinical Trial Information

临床试验信息

10.13.4

Safety and Efficacy

安全性与有效性

10.13.5

Analyst View

分析师观点

10.14

G207: Treovir and Matica Biotechnology

G207：Treovir 和 Matica 生物技术

10.14.1

Product Description

产品描述

10.14.2

Other Development Activities

其他开发活动

10.14.3

Clinical Development

临床开发

10.14.3.1

Clinical Trial Information

临床试验信息

10.14.4

Safety and Efficacy

安全性与有效性

10.14.5

Analyst View

分析师观点

10.15

Lerapolturev: Istari Oncology

勒拉波图雷夫：伊斯塔里肿瘤学

10.15.1

Product Description

产品描述

10.15.2

Other Development Activities

其他开发活动

10.15.3

Clinical Development

临床开发

10.15.3.1

Clinical Trial Information

临床试验信息

10.15.4

Safety and Efficacy

安全性与有效性

10.15.1

Analyst View

分析师观点

10.16

Nelitolimod (SD-101): TriSalus Life Sciences

内利托利莫德 (SD-101): TriSalus 生命科学

10.16.1

Product Description

产品描述

10.16.2

Other Developmental Activities

其他发展活动

10.16.3

Clinical Development

临床开发

10.16.3.1

Clinical Trial Information

临床试验信息

10.16.4

Safety and Efficacy

安全性与有效性

10.16.5

Analyst View

分析师观点

10.17

LOAd703 (Delolimogene mupadenorepvec): Lokon Pharma AB

LOAd703（Delolimogene mupadenorepvec）：Lokon Pharma AB

10.17.1

Product Description

产品描述

10.17.2

Other Development Activity

其他开发活动

10.17.3

Clinical Development

临床开发

10.17.3.1

Clinical Trial Information

临床试验信息

10.17.4

Safety and Efficacy

安全性与有效性

10.17.5

Analyst View

分析师观点

10.18

AdAPT-001: EpicentRx

AdAPT-001：EpicentRx

10.18.1

Product Description

产品描述

10.18.2

Other Developmental Activities

其他开发活动

10.18.3

Clinical Development

临床开发

10.18.3.1

Clinical Trial Information

临床试验信息

10.18.4

Safety and Efficacy

安全性与有效性

10.18.5

Analyst View

分析师观点

10.19

Bizaxofusp (MDNA55): Medicenna Therapeutics

10.19.1

Product Description

产品描述

10.19.2

Other Developmental Activities

其他开发活动

10.19.3

Clinical Development

临床开发

10.19.3.1

Clinical Trial Information

临床试验信息

10.19.4

Safety and Efficacy

安全性与有效性

10.19.5

Analyst View

分析师观点

10.20

CY-101 (CyPep-1): Cytovation ASA

CY-101（CyPep-1）：Cytovation ASA

10.20.1

Product Description

产品描述

10.20.2

Other Developmental Activities

其他开发活动

10.20.3

Clinical Development

临床开发

10.20.3.1

Clinical Trial Information

临床试验信息

10.20.4

Safety and Efficacy

安全性与有效性

10.20.5

Analyst View

分析师观点

10.21

VG161: Virogin Biotech

VG161：复诺健生物科技

10.21.1

Product Description

产品描述

10.21.2

Other Developmental Activities

其他开发活动

10.21.3

Clinical Development

临床开发

10.21.3.1

Clinical Trial Information

临床试验信息

10.21.4

Safety and Efficacy

安全性与有效性

10.21.5

Analyst View

分析师观点

10.22

CAN-2409: Candel Therapeutics

CAN-2409：Candel Therapeutics

10.22.1

Product Description

产品描述

10.22.2

Other Developmental Activities

其他开发活动

10.22.3

Clinical Development

临床开发

10.22.3.1

Clinical Trial Information

临床试验信息

10.22.4

Safety and Efficacy

安全性与有效性

10.22.5

Analyst View

分析师观点

10.23

LTX-315: Lytix Biopharma

LTX-315：Lytix生物制药公司

10.23.1

Product Description

产品描述

10.23.2

Other Developmental Activities

其他开发活动

10.23.3

Clinical Development

临床开发

10.23.3.1

Clinical Trial Information

临床试验信息

10.23.4

Safety and Efficacy

安全性与有效性

10.23.5

Analyst View

分析师观点

10.24

Multikine: CEI-SCI

Multikine：CEI-SCI

10.24.1

Product Description

产品描述

10.24.2

Other Developmental Activities

其他开发活动

10.24.3

Clinical Development

临床开发

10.24.3.1

Clinical Trial Information

临床试验信息

10.24.4

Safety and Efficacy

安全性与有效性

10.24.5

Analyst View

分析师观点

Intra-tumoral Cancer Therapies: Seven Major Market Analysis

肿瘤内癌症治疗：七大市场分析

11.1

Key Findings

主要发现

11.2

Market Outlook

市场展望

11.3

Key Market Forecast Assumptions

关键市场预测假设

11.3.1

Cost Assumptions and Rebates

成本假设与回扣

11.3.2

Pricing Trends

价格趋势

11.3.3

Analogue Assessment

模拟评估

11.3.4

Launch Year and Therapy Uptakes

上市年份与治疗吸收率

11.4

Conjoint Analysis

联合分析

11.5

Total Market Size of Intra-tumoral Cancer Therapies by Indications in the 7MM

7MM内按适应症划分的肿瘤内癌症治疗药物总市场规模

11.6

Total Market Size by Therapies in the 7MM

七大市场（7MM）按疗法划分的总市场规模

11.7

United States Market Size

美国市场规模

11.7.1

Total Market Size of Intra-tumoral Cancer Therapies by Indications in the United States

美国肿瘤内癌症治疗按适应症划分的总市场规模

11.7.2

Total Market Size by Therapies in the United States

美国各疗法的总市场规模

11.8

EU4 and the UK Market Size

EU4 和英国市场规模

11.8.1

Total Market Size of Intra-tumoral Cancer Therapies by Indications in EU4 and the UK

欧盟四大国家及英国肿瘤内癌症治疗药物的总市场规模（按适应症划分）

11.8.2

Total Market Size by Therapies in EU4 and the UK

欧盟四大市场和英国按治疗药物划分的总市场规模

11.9

Japan

日本

11.9.1

Total Market Size of Intra-tumoral Cancer Therapies by Indications in Japan

日本肿瘤内癌症治疗按适应症的总市场规模

11.9.2

Total Market Size by Therapies in Japan

日本各疗法的总市场规模

Unmet Needs

未满足的需求

SWOT Analysis

SWOT分析

KOL Views

KOL观点

Market Access and Reimbursement

市场准入与报销

15.1

The United States

美国

15.1.1

Centre for Medicare and Medicaid Services (CMS)

医疗保险和医疗补助服务中心 (CMS)

15.2

EU4 and the UK

EU4 与英国

15.2.1

Germany

德国

15.2.2

France

法国

15.2.3

Italy

意大利

15.2.4

Spain

西班牙

15.2.5

The United Kingdom

英国

15.3

Japan

日本

15.3.1

MHLW

厚生劳动省

15.5

Market Access and Reimbursement of Intra-tumoral Cancer Therapies

肿瘤内癌症疗法的市场准入与报销

15.5.1

United States: Assistance programs

美国：援助计划

15.5.2

United Kingdom: The National Institute for Health and Care Excellence (NICE) Assessment

英国：国家健康与护理卓越研究所 (NICE) 评估

15.5.3

Germany: The Federal Joint Committee (G-BA) resolutions

德国：联邦联合委员会 (G-BA) 决议

15.5.4

Japan: Chuikyo Assessment

日本：中银评估

Appendix

附录

16.1

Bibliography

参考文献

16.2

Report Methodology

报告方法论

DelveInsight Capabilities

德莱弗见解能力

Disclaimer

免责声明

About DelveInsight

关于DelveInsight

Related Reports